

MIRIKIZUMAB LONG-TERM IMPACT ON BOWEL URGENCY IN CROHN'S DISEASE AND ITS ASSOCIATION WITH CLINICAL AND OTHER EFFICACY OUTCOMES: RESULTS FROM THE VIVID-2 OPEN-LABEL EXTENSION STUDY

Simon Travis

UEG Week Berlin 2025

Poster

IBD

October 6, 2025

In patients with moderately to severely active Crohn's disease treated with mirikizumab for two years, over 50% achieved bowel urgency remission, which was significantly associated with higher rates of clinical remission, endoscopic remission, reduced fatigue, and improved quality of life.

KEY POINTS

- Over 50% of mirikizumab-treated patients achieved bowel urgency remission at week 104, with rates of 56% in week 52 endoscopic responders and 43% in non-responders
- Patients achieving bowel urgency remission had significantly higher clinical remission rates compared to those without bowel urgency remission: 96% versus 48% in the total group, 98% versus 54% in endoscopic responders, and 93% versus 41% in non-responders (all $p < 0.0001$)
- Bowel urgency remission was associated with significantly greater improvement in fatigue scores (FACIT-Fatigue mean change 12.2-12.3 versus 5.7-6.1, $p = 0.002$) and quality of life remission rates (IBDQ remission 82-89% versus 40-45%, $p < 0.0001$) across all patient subgroups
- Endoscopic remission at week 104 was significantly higher in patients with bowel urgency remission in the total group (34% versus 21%, $p = 0.018$), though differences were not statistically significant in the endoscopic non-responder subgroup
- This analysis is relevant for clinicians managing long-term outcomes in Crohn's disease patients, particularly regarding the relationship between symptom control and broader disease outcomes

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/cc714ee2-a814-11f0-a012-0242ac140006>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.